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Selected aspects of soft tissue sarcoma
Herman Suit1, Mukesh Harisinghani2, Thomas DeLaney1
This is a review of selected aspects of management of adult patients with soft tissue sarcoma and a consideration of several
recent developments. Mention is made of the evidence that there are unique gene clusters for at least several of the pathological
types of soft tissue sarcoma. This is judged to be a precursor of coming advances in genetic-based diagnosis and the potential
for prediction of biological behavior and response to the diverse treatment strategies. There has been remarkably rapid
development of clinically valuable imaging techniques (CT, MRI, dynamic MRI, MRS, and PET) separately or using image
fusion techniques which not only provide superior delineation of limits of extension of tumor but also their physiological status.
These techniques are likely to be integrated into the treatment delivery system to provide four-dimensional treatment planning
and delivery. One new method for determination of the involvement of lymph nodes by metastatic tumor is presented which
has high accuracy for nodes ≥6 mm in size. The rationale for employing radiation prior to or following resection is considered
and then the results at three years of the Canadian Phase III Trial of pre vs post operative radiation therapy for patients with
soft tissue sarcoma are presented. Similar local control but higher overall survival rates were found for the pre-operative arm;
however, there was a significantly higher rate of wound healing problems. Then the potential for major gains in the effectiveness
of radiation based on improving technologies against these tumors is considered. An anti-angiogenic agent (the antibody to
Vascular Endothelial Growth Factor 2, DC 101) has been shown to reduce significantly the radiation dose to inactivate two
human tumor xenografts. Further, studies on C3H mice bearing spontaneous autochthonous fibrosarcoma have shown
significant growth delay by that same antibody.
Mi´saki tkanek mi´kkich – wybrane zagadnienia
W pracy przedstawiamy wybrane zagadnienia dotyczàce mi´saków wywodzàcych si´ z tkanek mi´kkich, z uwzgl´dnieniem kilku
nowoÊci. Wspominamy o dowodach na istnienie unikalnych klasterów genów dla co najmniej kilku typów histopatologicznych
mi´saków. Sàdzi si´, ˝e jest to zapowiedê post´pu w zakresie diagnostyki genetycznej, który mo˝e pozwoliç oceniç biologi´
nowotworu oraz pozwoliç przewidzieç odpowiedê na ró˝ne metody terapeutyczne. Omawiamy równie˝ znaczny post´p
w dziedzinie technik obrazowania (CT, NMR, MRS i PET) tak osobno, jak i z zastosowaniem fuzji obrazów, umo˝liwiajàcej
nie tylko dok∏adne ustalenie granic naciekania guza, ale równie˝ ocen´ fizjologicznà. Nale˝y sàdziç, ˝e opisane techniki zostanà
wykorzystane w radioterapii, aby umo˝liwiç czterowymiarowe planowanie leczenia i u∏atwiç poda˝ dawek. Opisujemy nowà
metod´ oceny zaj´cia w´z∏ów ch∏onnych przez przerzuty. Metoda ta cechuje si´ bardzo du˝à dok∏adnoÊcià w przypadku
w´z∏ów o Êrednicy ≥6 mm. Przedstawiamy naszà opini´ na temat naÊwietlania przed i pooperacyjnego oraz wyniki zebrane
podczas trzech lat trwania Canadian Phase III Trial, porównujàcego wyniki przed i pooperacyjnego naÊwietlania u chorych
z mi´sakami tkanek mi´kkich. U chorych naÊwietlanych przed operacjà obserwowano d∏u˝sze prze˝ycia ca∏kowite i podobne
wyniki w zakresie wznowy miejscowej, niemniej wyst´powa∏o u nich znamiennie wi´cej powik∏aƒ gojenia si´ ran
pooperacyjnych. Nast´pnie przechodzimy do omówienia mo˝liwoÊci poprawy skutecznoÊci radioterapii w oparciu o techniki
naÊwietlania stosowane w mi´sakach tkanek mi´kkich, wspominajàc, ˝e zastosowanie specyficznego czynnika hamujàcego
angiogenez´ (przeciwcia∏o przeciw II czynnikowi wzrostu Êródb∏onka naczyniowego/Vascular Endothelial Growth Factor 2/
DC 101) przyczyni∏o si´ do znamiennego zmniejszenia dawki promieniowania, koniecznej do inaktywacji dwóch ludzkich
mi´saków przeszczepionych mi´dzygatunkowo. Co wi´cej, zastosowanie wspomnianego przeciwcia∏a u myszy szczepu C3H,
u których wystàpi∏y autochtoniczne, spontaniczne nowotwory o typie fibrosarcoma, znamiennie opóêni∏o wzrost guza.
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Introduction
The progressive growth of medical sub-specialization has
resulted in several medical centers with teams of
physicians, scientists and support staff who concentrate
their professional careers to improving the management
of patients with soft tissue sarcoma. These teams are
comprised of sarcoma specialists in orthopedic and
general surgery, adult and pediatric medical oncology,
radiation oncology, pathology, diagnostic radiology, tumor
biology, biostatistics, nursing, data and protocol
management. The expectation is that such concentration
of talent does result in a higher standard of patient care
and an acceleration of advances in this field. Such
commitment of time and effort to this one category of
tumors has, to this date, had a clearly positive impact.
In this paper, consideration is to be given to a several
selected aspects of the present and potential future care
of patients with soft tissue sarcoma.
Diagnosis
D i a g n o s t i c  R a d i o l o g y
Current imaging studies employed in nearly all patients
suspected of having a soft tissue sarcoma are plain films,
CT and MRI (with contrast) and increasingly PET.
Dynamic MRI and MRS imaging are being evaluated
and with promising results. Changes in tumor volume
following radiation have not been established as useful
predictors of the radiation effect in terms of the critical
end-point, viz clonogen cell kill.
Presently available imaging methods do provide
clinically useful information as to the sarcoma size, exact
anatomic site, local pattern of extension and distribution
of necrosis. In the not distant future, the character of
metabolic activity throughout the tumor should become
available.
Here, mention is made of a potentially important
advance in assessment of the nodal status. Soft tissue
sarcoma infrequently has metastatic disease in regional
lymph nodes. However, the frequency is clinically
important for grade III sarcomas >5 cm and all epithe-
lioid sarcomas and rhabdomyosarcomas [1]. A new
technique for imaging of the regional nodes is briefly
described which will be tested on sarcoma patients in the
near future. Harisinghani et al at MGH employ an iron
oxide compound which is administered systemically and is
taken-up nearly uniformly by lymph nodes throughout
the body [2]. On post-injection MRI, the normal nodes
are uniformly black. Any portion of the node involved
by tumor does not take up iron and is, accordingly,
visualized as white due to the absence of iron. An
example of this new imaging method is presented in
Figures 1a and b from a study of the axillary nodes in
a patient with carcinoma of breast. As shown in Fig. 1 a,
only size and number of the nodes can be determined
from the MRI prior to injection of the contrast agent.
Following injection of the iron oxide, the normal nodes
are black, Fig. 1 b. In one node, there is a white region, viz
the portion of the node, which did not collect the iron
oxide. This node was proven to be a site of metastatic
tumor. Harisinghani and team have had a >95% accuracy
in studies of patients with pelvic cancers in the iden-
tification of nodes of ≥6 mm which have metastatic tumor.
Pa t h o l o g y
Histopathologic diagnosis is a critical component of the
patient management. The biopsy needs to be planned by
an experienced member of the team in order that there is
no negative impact on the definitive treatment due to
improper placement of the core needle track or scar for
an incisional biopsy. That is, these have to be sited so as to
be included in the surgical specimen or in the radiation
treatment volume. Regrettably, there is not a rare patient
Figure 1a
Figure 1. MRI images of the axilla after injection of an iron oxide contrast agent into a patient with carcinoma of the breast. Figure 1a is prior to
injection and clearly demonstrates normal appearing nodes. In Figure 1b, the normal nodes are black except for a portion of one node that is devoid
of contrast, the site of a focus of metastatic tumor
Figure 1b
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whose biopsy site forces a less than optimal definitive
treatment.
Pathological diagnosis is becoming progressively
more objective with the use of immunohistochemical
staining, karyotyping and cDNA array genetic charac-
terization. From the latter, the expectation is not only
more accurate diagnosis of tumor type, but also reliable
information for prediction of the biological behavior and
quantitation of response to the planned treatment
(radiation, drug, biological agent, immunologic, genetic,
etc.). There appears to have been substantial achievement
by genetic techniques in the definition of the type for
several categories of tumors. The Vancouver and Stanford
groups have reported in Lancet [3] their analysis of the
expression of 5520 genes in a series of 41 soft tissue
sarcomas by cDNA array technology. Quite impressively
their data indicate that there are distinctive clusters of
genes for monophasic synovial sarcomas (104 genes,
including synovial sarcoma X (SXX), retinoic acid
pathway genes and epidermal growth factor receptor
gene) and gastrointestinal stromal tumors (125 genes}. Of
special interest was the finding that of 11 leiomyo-
sarcomas, 6 expressed a cluster of 24 genes associated
with muscle structure and function while most of the
other 5 did not exhibit expression of any of these genes,
but were, however, Desmin positive. Within a short time,
there will almost certainly be accrual of substantial
additional data which will provide the basis for
increasingly objective criteria for designation of the
pathological type of sarcoma. Not as rapid in the
realization will be the availability of new genetic infor-
mation on the tumor cells and the cells from several
relevant normal tissues which will prove to be of
enormous value in planning the management strategy of
the sarcoma patient.
Management of the primary soft tissue sarcoma
(non rhabdomyosarcoma), stage M0
There are two general goals for the management of
patients with soft tissue sarcoma: 1) eradication of all
local, regional and distant disease and 2) the production
of no complications and minimal functional and cosmetic
deficit. At present all treatment methods have some
associated short and long term morbidity. Defining the
management strategy which realizes the best available
balance between cure probability vs overall functio-
nal/cosmetic outcome will rely on an increasingly complex
data base for each patient.
Surgical resection is recommended for virtually all
Stage M0 patients. To decrease the extent of resection
of grossly uninvolved normal tissues, surgery is combined
with radiation in a large proportion of patients. The
rationale is the high frequency of microscopic extension of
sarcoma beyond the limits of the gross lesion (imaging
and clinical examination). According to present under-
standing, permanent local control requires the removal or
eradication of 100.0% of tumor clonogens. Thus, surgical
margins must be wide of the grossly evident disease to
include all of the sub-clinical disease. These wider margins
mean further reduction in the functional and cosmetic
outcome. That radiation in moderate dose levels is
effective in killing all of the cells in the microextensions
has been established. Hence, a combination of less than
radical resection with moderate radiation doses is an
effective approach for control of the local disease. Two
immediate questions are 1) what is the evidence that
radiation is a useful modality against soft tissue sarcomas;
and 2) if effective, what is the most effective sequence
of the two modalities?
The early experience with radiation in the treatment
of patients with soft tissue sarcoma was interpreted by
clinicians to show that radiation was of no clinical value
for those tumors [4]. The basis for that opinion up to the
1960's was due to: 1) treatment of large lesions; 2) use of
radiation alone; 3) due to technical factors, the radiation
dose was low (<50 Gy); and 4) efficacy was judged by
speed of regression. None of these factors apply today.
Ruka [5] determined the in vitro survival fraction at 2 Gy
for a series of cell lines derived from soft tissue sarcomas
and a series from carcinomas of the breast. There was
no difference in the radiation sensitivity between the two
series of cell lines, as shown in Figure 2. There is now
ample documentation that resection of small carcinomas
of the breast and of soft tissue sarcomas (≤4 cm) and
post-operative radiation therapy yields local control
probabilities of ≥90% at 5 years [6]. Thus, the available
evidence suggests that malignant epithelial and me-
senchymal tumors (non-exophytic) of a specified volume
require approximately the same dose to achieve a defined
tumor control probability.
Surgery may be recommended as the sole treatment
for lesions, which can be resected with widely negative
margins while retaining good function and cosmesis.
Unfortunately, sarcomas which meet this requirement
are uncommon, viz, small lesions in relatively fleshy parts.
To avoid a margin which is close at some point requires
loss of important anatomic structures in a high proportion
of sarcomas at the elbow, wrist, hand, ankle, foot and
many sites in the head and neck region. Thus, even for
Figure 2. Cumulative frequency of survival fractions at 2 Gy of cell
lines derived from carcinomas of the breast and from soft tissue
sarcomas as determined in vitro [5]
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small low-grade lesions at these sites, conservative surgery
and radiation would be expected to yield better functional
results for many such patients. Generally, satisfactory
margins for surgery alone are judged to be the closest
margin which is proven to be negative at ≥2 cm. Our
experience has been that the narrowest margin is rarely
greater than 10 mm even for lesions of the thigh and
torso. A closer margin may be entirely acceptable when
that margin is an intact fascial plane or bone.
For the great majority of sarcomas, the preferred
management by the MGH Sarcoma team is the com-
bination of pre-operative radiation and surgery. Our
experience is that radiation administered pre-operatively
has several significant advantages relative to post-
operative irradiation. These include:
1. The volume of irradiated tissues is substantially less
due to the fact that the treatment volume is planned
entirely on the defined volume of tumor (gross and
sub-clinical) and the anatomic site. No consideration is,
of course, given to the tissue planes to be handled
subsequently by the surgeon. In contrast post-operative
treatment includes the entire surgical bed. That is, the
rationale for administration of radiation post-ope-
ratively is that tumor cells had been spilled into the
tumor bed and or there are microscopic foci in the
tissues adjacent to the surgical margins. The latter
constitutes "cut-through" of tumor. The implication is
tumor cell contamination of the entire tumor bed. The
difference in treatment volume has been quantitated in
the study by Nielsen et al from the Ontario Cancer
institute [7] and shown to be substantial. The lesser
volume of irradiated tissues results in less severe and
less frequent late radiation changes in normal tissues.
2. The radiation dose is significantly lower in nearly all
patients. Namely, for pre-operative irradiation the
dose is ~50 Gy in 5 weeks vs ~66 Gy for post-
operative irradiation to margin negative patients.
3. The basis for the higher dose in post-operative
treatment is, perhaps, that during the 2-4 weeks
between surgery and the start of post-operative
treatment, the residual tumor clonogens are bathed
in all of the cytokines the local tissues can muster to
accelerate wound healing. There is virtual certainty
that those same cytokines accelerate tumor clonogen
proliferation. The result is that by the start of post-
operative radiation, there are a larger number of tumor
cells, which must be killed than obtains for radiation
administered prior to surgery.
4. There is essentially no risk of autotransplantation of
tumor in the surgical bed or of distant metastasis
developing from cells spilled into the tumor bed or
exfoliated into the blood vascular spaces during the
surgical procedure. Comparatively low doses, e g, ~2
Gy x 10, appear to be effective in prevention of wound
seeding. This contrasts with the need for some 50 Gy
to inactivate very small foci of established tumor.
5. There is no delay in the start of radiation treatment.
For large tumors or in anatomic sites with poor or
compromised vascular supply, there may be long delays
before healing is adequate for the commencement of
the post-operative radiation. We have seen gross tumor
regrowth prior to the start of radiation therapy when
wound healing has been slow.
6. Some inoperable lesions may become operable follo-
wing the pre-operative treatment.
7. Pre-operative treatment is much more likely to involve
multidisciplinary planning of overall strategy.
8. This approach does demand special care in planning
the treatment so as to include the minimum of normal
tissues not judged to be involved by sub-clinical
extensions of tumor in the treatment volume. This
decreases the probability of delay in wound healing.
Further, the surgeon needs to handle the irradiated
tissues with greater care than when operating on
unirradiated tissues. Additionally, the wound needs to
be closed in layers and to avoid tension. This latter
may require use of vascularized flaps, grafts etc.
Microvascular surgery is making significant con-
tributions to the success of grafting in difficult
circumstances.
There are advantages to radiation given following
surgical resection. These include:
1. There is no delay to surgery. For some patients, there
is anxiety to "have the tumor out".
2. The complete and untreated tumor specimen is
available for pathological study.
3. Were chemotherapy given pre-operatively, an estimate
of the response to the drugs may be made
4. There is no radiation impairment of wound healing.
O'Sullivan et al, have published the preliminary
results from the important Canadian Phase III trial
designed to assess the relative efficacy of treatment of
patients with extremity soft tissue sarcoma stage M0 by
pre vs post operative radiation therapy [8]. There were 94
and 96 patients for the pre and the post operative arms,
respectively. Treatment was 50 Gy at 2 Gy/fraction over ~
5 weeks pre-operatively vs 66 Gy post-operatively also at
2 Gy /fraction. At a median follow-up of 3.3 years, there
was comparable local control at ~90%. Overall survival
was 85% vs 72% favoring the pre-operatively treated
patients. There was a significantly higher wound healing
delay in the pre-operatively irradiated patients, viz, 35% vs
17%. Longer-term follow-up is required to assess the
impact of the much larger treatment volumes and higher
dose in patients treated post-operatively. Importantly,
the available evidence from their trial is that the late
fibrosis is less severe in the pre-operatively irradiated
patients. This is as expected as the pre-operative group
had a substantially lower dose and also a smaller
treatment volume
Bujko et al, [9] analyzed the surgical wound com-
plication frequency among 202 patients managed at
Massachusetts General Hospital by pre-operative radia-
tion and surgical resection. The incidence of complication
was also 37%. This is comparable to the Canadian
experience vide supra. Of these 16% required some form
of surgical procedure to facilitate healing. Our conclusion
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is that there must be special care with the irradiated
tissue, namely avoidance of tension in closure, closure of
the wound in layers, and use of flaps etc, to avoid tension
and secure good approximation of the sides of the defect
so as to minimize any seroma.
Potential for further reductions in treatment related
morbidity
The incidence and grade of morbidity secondary to the
radiation is almost certainly to decrease in the coming
1-2 decades due to the impressive technical advances in
the planning and delivery of radiation therapy. These
improvements are to be due to: 1) major advances in
imaging technology, e g, fusion of images from diverse
methods, more accurate assessment of the anatomical
extent of tumor and the biological characteristics of the
tumor; 2) ability to assess tumor response (other than
change in size) during the progress of the treatment; 3)
much wider availability of IMRT and proton radiation
beams; and 4) four dimensional treatment planning and
delivery, i e, techniques to assure that the target is
correctly positioned in the treatment beam throughout
each treatment session. Thus, the treatment volume will
include a smaller volume of adjacent normal tissues. For
example for a thigh soft tissue sarcoma, only a small
proportion of the adjacent bone need be within the high
dose volume, and thereby diminish the frequency of
fractures through bone uninvolved by tumor (even bones
which have not had periosteal stripping. Additionally,
there should be vastly improved strategies for timing of
the administration of drugs or agents relative to each
irradiation session.
Management of occult metastatic sarcoma in the
stage M0 patients
Due to the important probability of the presence of
metastatic disease in patients with intermediate to high-
grade sarcomas of 5 cm or larger who are staged as M0.
Many centers administer intensive chemotherapy to
selected categories of such patients.
The question for soft tissue sarcomas (non-rhab-
domyosarcoma) is the relative gain in long-term freedom
from distant metastasis in local control patients versus
serious morbidity due to the systemic therapy. Unfor-
tunately, chemotherapy has not been as effective for the
soft tissue sarcoma as for osteogenic sarcoma in
enhancement of disease-free survival at 10 years. Even so
there does appear to be a real benefit of neo-adjuvant
chemotherapy.
At MGH, our current practice for patients with
intermediate to high-grade sarcomas of ≥8 cm and Stage
M0 is to recommend MAID chemotherapy and radiation
prior to resection. These patients have a high probability
of developing distant metastasis even though local control
is achieved. Accordingly, we administer both the
chemotherapy and radiation pre-operatively, i.e., to
tumors with unperturbed circulation. Our current
protocol is 3 cycles of MAID and two cycles of radiation
prior to surgery: one radiation cycle is given between
MAID cycle one and two and then a second between
MAID cycles 2 and 3. Each radiation cycle is 2 Gy x 11,
i e, a total of 44 Gy pre-operatively. Were there to be
a positive surgical margin, a post-operative boost dose
of 16 Gy is given before MAID cycle 4-6. Generally, this
program is with serious hematologic morbidity [10] and an
increased delay in wound healing. This was of the same
order as found be Bujko [9].
DeLaney et al have updated the outcome analysis in
48 patients with large high grade sarcomas of the
extremities treated at Massachusetts General Hospital
on the radiation – MAID pre-operative protocol. There
were 48 control patients who were treated over a similar
time period and matched for sarcoma grade and size.
The five-year local control results were 92% and 86%
(NS), while the metastasis free survival was 75% and 44%
respectively (p<0.01), for the test and control patients
(DeLaney submitted for publication 2002). These data
indicate that for the patients with grade II-III sarcomas,
the MAID chemotherapy given pre-operatively does
effect an increment in metastasis free survival.
At present, there are substantial numbers of clinical
trials of new agents or combinations of established agents
by the US NCI and the EORTC. These include trials of:
Antineoplastons A 10 and AS2-1; Ecteinascidin 743,
Irnotecan, Rosiglitazone, Temozolimide, TNF α, hyper-
thermia, limb perfusion with a variety of agents and
a spectrum of anti-angiogenic agents. There is a high
likelihood of positive yields from, at least, a few of these
diverse efforts.
Anti-angiogenic agents
Brief mention is made of two recent laboratory results
from the MGH radiation oncology group. Kozin et al,
[11] first demonstrated a significant reduction in the
radiation dose required to inactivate two human tumor
xenografts by the combination of radiation and DC 101,
an anti-vascular endothelial growth receptor-2 antibody.
Izumi et al, have shown a significant and marked growth
delay of the spontaneous autochthonous fibrosarcoma of
the C3H mouse by DC 101 (submitted for publication,
August 2002}. These findings are a positive indication
that some benefit can be expected at the clinical level for
use of one or more anti-angiogenic agent against
appropriately selected tumors.
Herman Suit MD
Radiation Oncology
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
USA
e-mail: suit.herman@mgh.harvard.edu
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